High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|68|1|71-78

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.1, 2005-04, pp. : 71-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 197-203

Karger

Access to resources Recommend Favorite

Docetaxel Weekly with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 8-9, 2007-09 ,pp. : 407-408

Karger

Access to resources Recommend Favorite

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

By  

Oncology, Vol. 70, Iss. 5, 2007-01 ,pp. : 330-338

Karger

Access to resources Recommend Favorite